News
Stockhead on MSN40m
Pitt Street sees strong upside as Prescient advances phase 2a cancer trialPitt Street Research sees strong upside in Prescient Therapeutics as one of the most advanced oncology companies on the ASX .
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback